# p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

Article · Robert J. Ihry, Kathleen A. Worringer, Max R. Salick, Elizabeth Frias, Daniel J. Ho, Kraig M. Theriault, Sravya Kommineni, Julie Chen, Marie Sondey, Chaoyang Ye, Ranjit Randhawa, Tripti Kulkarni, Zinger Yang, Gregory McAllister, Carsten Russ, John S. Reece-Hoyes, William C. Forrester, Gregory R. Hoffman, Ricardo E. Dolmetsch, Ajamete Kaykas

- Archive id: doi:10.1038/s41591-018-0050-6
- Published: 2018-06-08
- Venue: Nature Medicine
- DOI: https://doi.org/10.1038/s41591-018-0050-6
- PMID: 29892062
- Citations: 977
- Source URL: https://doi.org/10.1038/s41591-018-0050-6
- PDF: https://www.biorxiv.org/content/biorxiv/early/2017/07/26/168443.full.pdf
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [CRISPR & Gene-Editing Therapies](https://space-kitty.com/topics/gene-editing-therapies)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.